risankizumab
abbvie
['risan', 'crohn', 'ibd']
up next, marc ferrante presents further analyses of the ph 3 risankizumab crohn's disease programme. this post hoc analysis examines response by previous biologic therapy #uegweek #ibd #gitwitter 
The Lancet Gastroenterology & Hepatology publishes high-quality peer-reviewed research and reviews, comment, and news #gastroenterology #hepatology. IF=45.042